We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA intends to clarify its expectations for demonstrating the interchangeability of biosimilars with reference products, an FDA official said. Read More
The UK’s price watchdog recommended against the reimbursement of Roche’s Cotellic and Zelboraf for the treatment of BRAF V600 mutation-positive melanoma, citing the expensive list price for the products. Read More
The New York attorney general’s office is conducting an investigation to determine if Mylan engaged in anticompetitive practices when entering contracts to sell its allergy therapy EpiPen to schools. Read More
The UK’s price watchdog has recommended reimbursement for Bayer’s prostate cancer drug Xofigo for an expanded indication, provided that the company delivers discounted prices as promised. Read More
Presidential hopeful Hillary Clinton has unveiled a plan to rein in exorbitant drug costs for lifesaving treatments that would penalize drugmakers for price-gouging. Read More
The California Supreme Court ruled that state courts have the jurisdiction to hear cases filed by out-of-state residents, clearing the path for an amended suit against Bristol-Myers Squibb that contends the company’s blood-thinner Plavix led to patient injuries. Read More
Despite Mylan’s efforts to quell criticism, U.S. lawmakers continue to press the company and the FDA for greater transparency on the cost of the company’s EpiPen epinephrine auto-injector. Read More